AstraZeneca PLC
Bear Case (25th pct.)
-37.1% vs price
Base Case (Median)
-32.6% vs price
Bull Case (75th pct.)
-26.3% vs price
◇ = Current price | |Bear |Base | Bull
| Method | Est. Value | vs Price | Weight |
|---|---|---|---|
| DCF (Discounted Cash Flow) | $112.34 | -40.8% | High (40%) |
| PE Comparable | $145.83 | -23.2% | Medium (25%) |
| Growth Trajectory DCF | $280.34 | 47.6% | Medium (20%) |
| Graham Number | $68.02 | -64.2% | Medium (40%) |
| EV/EBITDA | $127.93 | -32.6% | Medium (20%) |
| EV/FCF | $134.23 | -29.3% | Medium (20%) |
| Earnings Power Value | $126.38 | -33.4% | Medium (50%) |
Based on 7 out of 8 methods, AZNCF appears overvalued at the current price of $189.90. The base case fair value of $127.93 implies 32.6% downside.
Bear/base/bull cases represent the 25th, 50th, and 75th percentile of available method estimates. This is not financial advice. Valuation is inherently uncertain.